Beijing-based Sinovac Life Sciences Co., Ltd. on Wednesday filed an application with Chinese authorities for conditional marketing authorization of its anti-COVID-19 vaccine CoronaVac.

The application has been received by the National Medical Products Administration (NMPA), according to Sinovac Biotech Ltd., which has a majority stake in the vaccine producer.

The inactivated vaccine CoronaVac has made progress in phase three clinical trials overseas, showing a good level of safety after inoculation, according to a company statement.

Fourteen days after the inoculation of two doses of CoronaVac, the effectiveness of the vaccine in protecting against diseases caused by COVID-19 has met the relevant technical standards laid out by the World Health Organization and the requirements of the NMPA, the statement said.


Please enter your comment!
Please enter your name here